Skip to Content
Merck
All Photos(1)

Documents

L-021

Supelco

Lorazepam glucuronide solution

100 μg/mL in acetonitrile: water (1:1), ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C21H18Cl2N2O8
CAS Number:
32781-79-6
Molecular Weight:
497.28
MDL number:
MFCD02682126
UNSPSC Code:
41116107
PubChem Substance ID:
329817344
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland)

concentration

100 μg/mL in acetonitrile: water (1:1)

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

O[C@@H]1[C@@H](O)[C@H](OC2N=C(c3ccccc3Cl)c4cc(Cl)ccc4NC2=O)O[C@@H]([C@H]1O)C(O)=O

InChI

1S/C21H18Cl2N2O8/c22-8-5-6-12-10(7-8)13(9-3-1-2-4-11(9)23)25-19(18(29)24-12)33-21-16(28)14(26)15(27)17(32-21)20(30)31/h1-7,14-17,19,21,26-28H,(H,24,29)(H,30,31)/t14-,15-,16+,17-,19?,21-/m0/s1

InChI key

IWOJSSFCRQKNKN-IFBJMGMISA-N

Related Categories

General description

Lorazepam glucuronide is a primary urinary metabolite of lorazepam, a benzodiazepine often prescribed for treatment of anxiety disorders. This Certified Spiking Solution® is suitable for use as starting material in calibrators or controls for a variety of LC/MS or GC/MS applications from clinical toxicology and forensic analysis to urine drug testing.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.
Description
Pricing

B-033

Benzodiazepine Multi-component Mixture-8 solution, 250 μg/mL each component in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

L-901

Lorazepam solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

L-902

Lorazepam-d4 solution, 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

L-907

Lormetazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

L-911

Lorazepam-d4 solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

D-163

Delorazepam-D4 solution, 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

L-059

Lorazepam-D4 glucuronide lithium salt solution, 100 μg/mL (Acetonitrile:Water (50:50) (v/v), (as free acid)), certified reference material, ampule of 1 mL, Cerilliant®

Pictograms

FlameExclamation mark
GHS02,GHS07

Signal Word

Danger

Hazard Statements

H225,H302,H319

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

55.4 °F - closed cup

Flash Point(C)

13 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

R Verbeeck et al.
British journal of clinical pharmacology, 3(6), 1033-1039 (1976-12-01)
To evaluate the effect of end-stage renal insufficiency and haemodialysis on the elimination of lorazepam, single oral doses of the drug (2.5 mg) were administered to normal subjects and patients with chronic renal failure (CC(r) : less than 2 ml/min)
In vitro binding of lorazepam and lorazepam glucuronide to cholestyramine, colestipol, and activated charcoal.
R J Herman et al.
Pharmaceutical research, 8(4), 538-540 (1991-04-01)
A J Cummings et al.
British journal of clinical pharmacology, 12(4), 511-515 (1981-10-01)
1 An investigation has been made of the excretion of alpha-methyldopa, alpha-methyldopa sulphate, lorazepam and lorazepam glucuronide in the urine of neonates. 2 The rate of elimination of both the drugs in the newborn is slow compared with the adult
R A Branch et al.
The Journal of laboratory and clinical medicine, 102(5), 805-812 (1983-11-01)
The relative effects of pretreatment with allyl alcohol and carbon tetrachloride on oxidative and glucuronide metabolism of lorazepam have been compared in the isolated perfused rat liver. Livers from rats pretreated for 24 hr with allyl alcohol (1.8 ml/kg, 1:50
G Morrison et al.
Clinical pharmacology and therapeutics, 35(5), 646-652 (1984-05-01)
The effect of renal disease on lorazepam kinetics was assessed in three groups: six normal subjects, six patients with renal impairment, and four functionally anephric patients. Subjects received single 1.5- or 3-mg intravenous and oral doses; eight subjects (four normal
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service